{{Rsnum
|rsid=11045879
|Gene=SLCO1B1
|Chromosome=12
|position=21229685
|Orientation=plus
|GMAF=0.2525
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=SLCO1B1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.9 | 31.0 | 68.1
| HCB | 22.6 | 45.3 | 32.1
| JPT | 16.8 | 44.2 | 38.9
| YRI | 1.4 | 27.9 | 70.7
| ASW | 5.3 | 31.6 | 63.2
| CHB | 22.6 | 45.3 | 32.1
| CHD | 28.4 | 40.4 | 31.2
| GIH | 0.0 | 12.9 | 87.1
| LWK | 3.6 | 29.1 | 67.3
| MEX | 1.7 | 19.0 | 79.3
| MKK | 4.5 | 28.2 | 67.3
| TSI | 3.9 | 37.3 | 58.8
| HapMapRevision=28
}}
{{PMID Auto
|PMID=19901119
|Title=Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects
|OA=1
}}

{{PharmGKB
|RSID=rs11045879
|Name_s=OATP1B1: intronic C/T
|Gene_s=SLCO1B1
|Feature=Intron
|Evidence=PubMed ID:19901119
|Annotation=Risk or phenotype-associated allele: T allele, with additive genotypic effect. Phenotype: Genome-wide analysis of 398,699 germline SNPs showed association of the rs11045879 T allele increased methotrexate (MTX) plasma clearance, with additive effect per T allele (increase of 13.1 mL/min/m(2) per allele in 434 subjects), after adjusting for age, race, sex, and MTX regimen. Variants rs11045879 and rs4149081 were in linkage disequilibrium (r(2) = 1). The T allele was associated with increased risk of gastrointestinal toxicity (mucositis) (OR = 16.4, p = 0.004). Pharmacokinetics differed by ethnicity (MTX clearance: African>Caucasian). Study size: 434 (discovery cohort), 206 (independent validation cohort), 640 (combined cohort). Study population/ethnicity: Multiethnic children with ALL (5.92 median age , 1.02-18.85 range) given 3,014 courses of methotrexate at 2-5 g/m(2) enrolled in Tennessee. Significance metric(s): increased MTX clearance: p = 1.7 x 10(-10) (n = 434), p = 0.018 (n = 206), p = 8.2 x 10(-11) (n = 640); increased GI toxicity: OR = 16.4, p = 0.004. Type of association: CO; GN; PK; ADR; TOX
|Drugs=methotrexate
|Drug Classes=
|Diseases=Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA165110326
}}

{{PMID Auto
|PMID=21387541
|Title=Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia
}}

{{PMID|19419973|OA=1
}} Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11045879
|overall_frequency_n=22
|overall_frequency_d=126
|overall_frequency=0.174603
|n_genomes=20
|n_genomes_annotated=0
|n_haplomes=21
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto GWAS
  |PMID=23281178
  |Trait=Metabolite levels
  |Title=A genome-wide assessment of variability in human serum metabolism.
  |RiskAllele=C
  |Pval=5E-15
  |OR=NR
  |ORtxt=NR
  }}

{{PMID Auto
|PMID=23222202
|Title=Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}